{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:27:25Z","timestamp":1760909245509,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T00:00:00Z","timestamp":1595635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T00:00:00Z","timestamp":1595635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the CAMS Innovation Fund for Medical Sciences","award":["2016-I2M-1-001"],"award-info":[{"award-number":["2016-I2M-1-001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s00277-020-04195-z","type":"journal-article","created":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T15:03:26Z","timestamp":1595689406000},"page":"2847-2857","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Event-free survival at 24\u00a0months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma"],"prefix":"10.1007","volume":"99","author":[{"given":"Haizhu","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianliang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changgong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohui","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Gui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8450-7583","authenticated-orcid":false,"given":"Yuankai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,25]]},"reference":[{"key":"4195_CR1","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/ejh.12722","volume":"96","author":"R Bassan","year":"2016","unstructured":"Bassan R, Maino E, Cortelazzo S (2016) Lymphoblastic lymphoma: an updated review on biology, diagnosis, and treatment. Eur J Haematol 96:447\u2013460","journal-title":"Eur J Haematol"},{"key":"4195_CR2","first-page":"1015","volume":"23","author":"JW Sweetenham","year":"2009","unstructured":"Sweetenham JW (2009) Treatment of lymphoblastic lymphoma in adults. Oncology (Williston Park) 23:1015\u20131020","journal-title":"Oncology (Williston Park)"},{"key":"4195_CR3","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/PPO.0b013e31826b1232","volume":"18","author":"CA Portell","year":"2012","unstructured":"Portell CA, Sweetenham JW (2012) Adult lymphoblastic lymphoma. Cancer J 18:432\u2013438","journal-title":"Cancer J"},{"key":"4195_CR4","doi-asserted-by":"publisher","first-page":"4379","DOI":"10.1182\/blood-2002-01-0110","volume":"99","author":"D Hoelzer","year":"2002","unstructured":"Hoelzer D, Gokbuget N, Digel W et al (2002) Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood 99:4379\u20134385","journal-title":"Blood"},{"key":"4195_CR5","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.3324\/haematol.10882","volume":"92","author":"M Hunault","year":"2007","unstructured":"Hunault M, Truchan-Graczyk M, Caillot D, Harousseau JL, Bologna S, Himberlin C, Guyotat D, Berthou C, Casassus P, Baranger L, Bene MC, Ifrah N, Gyan E, for the GOELAMS Group (2007) Outcome of adult T-lymphoblastic lymphoma after acute lymphoblastic leukemia-type treatment: a GOELAMS trial. Haematologica 92:1623\u20131630","journal-title":"Haematologica"},{"key":"4195_CR6","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1200\/JCO.2015.61.5385","volume":"34","author":"S Lepretre","year":"2016","unstructured":"Lepretre S, Touzart A, Vermeulin T, Picquenot JM, Tanguy-Schmidt A, Salles G, Lamy T, B\u00e9n\u00e9 MC, Raffoux E, Huguet F, Chevallier P, Bologna S, Bouabdallah R, Benichou J, Bri\u00e8re J, Moreau A, Tallon-Simon V, Seris S, Graux C, Asnafi V, Ifrah N, Macintyre E, Dombret H (2016) Pediatric-like acute lymphoblastic leukemia therapy in adults with lymphoblastic lymphoma: the GRAALL-LYSA LL03 study. J Clin Oncol 34:572\u2013580","journal-title":"J Clin Oncol"},{"key":"4195_CR7","doi-asserted-by":"publisher","first-page":"E595","DOI":"10.1002\/ajh.24833","volume":"92","author":"P Jain","year":"2017","unstructured":"Jain P, Kantarjian H, Jain N, Short NJ, Yin CC, Kanagal-Shamanna R, Khoury J, Konopleva M, Sasaki K, Kadia TM, Garris R, Pierce S, Estrov Z, Wierda W, Cortes J, O'Brien S, Ravandi F, Jabbour E (2017) Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens. Am J Hematol 92:E595\u2013E597","journal-title":"Am J Hematol"},{"key":"4195_CR8","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1038\/sj.leu.2403095","volume":"17","author":"S Le Gouill","year":"2003","unstructured":"Le Gouill S, Lepretre S, Briere J et al (2003) Adult lymphoblastic lymphoma: a retrospective analysis of 92 patients under 61 years included in the LNH87\/93 trials. Leukemia 17:2220\u20132224","journal-title":"Leukemia"},{"key":"4195_CR9","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1200\/JCO.1992.10.7.1078","volume":"10","author":"P Morel","year":"1992","unstructured":"Morel P, Lepage E, Brice P, Dupriez B, D'Agay MF, Fenaux P, Gosselin B, Bauters F, Gisselbrecht C (1992) Prognosis and treatment of lymphoblastic lymphoma in adults: a report on 80 patients. J Clin Oncol 10:1078\u20131085","journal-title":"J Clin Oncol"},{"key":"4195_CR10","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41598-018-19565-x","volume":"8","author":"M Dong","year":"2018","unstructured":"Dong M, Zhang X, Yang Z, Wu S, Ma M, Li Z, Chang Y, Wang X, Li L, Li X, Zhang M, Chen Q (2018) Patients over 40 years old with precursor T-cell lymphoblastic lymphoma have different prognostic factors comparing to the youngers. Sci Rep 8:1088","journal-title":"Sci Rep"},{"key":"4195_CR11","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/annonc\/mdl426","volume":"18","author":"KW Song","year":"2007","unstructured":"Song KW, Barnett MJ, Gascoyne RD, Chhanabhai M, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Voss NJ, Connors JM (2007) Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes. Ann Oncol 18:535\u2013540","journal-title":"Ann Oncol"},{"key":"4195_CR12","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1182\/blood-2003-12-4428","volume":"104","author":"DA Thomas","year":"2004","unstructured":"Thomas DA, O'Brien S, Cortes J, Giles FJ, Faderl S, Verstovsek S, Ferrajoli A, Koller C, Beran M, Pierce S, Ha CS, Cabanillas F, Keating MJ, Kantarjian H (2004) Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 104:1624\u20131630","journal-title":"Blood"},{"key":"4195_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00277-011-1252-x","volume":"91","author":"S Cortelazzo","year":"2012","unstructured":"Cortelazzo S, Intermesoli T, Oldani E, Ciceri F, Rossi G, Pogliani EM, Mattei D, Romani C, Cortelezzi A, Borlenghi E, Corti C, Peruta B, Spinelli O, Rambaldi A, Bassan R (2012) Results of a lymphoblastic leukemia-like chemotherapy program with risk-adapted mediastinal irradiation and stem cell transplantation for adult patients with lymphoblastic lymphoma. Ann Hematol 91:73\u201382","journal-title":"Ann Hematol"},{"key":"4195_CR14","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/cncr.11615","volume":"98","author":"J Mora","year":"2003","unstructured":"Mora J, Filippa DA, Qin J, Wollner N (2003) Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at memorial-Sloan-Kettering Cancer Center. Cancer 98:1283\u20131291","journal-title":"Cancer"},{"key":"4195_CR15","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1038\/s41375-019-0466-0","volume":"33","author":"XP Tian","year":"2019","unstructured":"Tian XP, Huang WJ, Huang HQ, Liu YH, Wang L, Zhang X, Lin TY, Rao HL, Li M, Liu F, Zhang F, Zhong LY, Liang L, Lan XL, Li J, Liao B, Li ZH, Tang QL, Liang Q, Shao CK, Zhai QL, Cheng RF, Sun Q, Ru K, Gu X, Lin XN, Yi K, Shuang YR, Chen XD, Dong W, Sang W, Sun C, Liu H, Zhu ZG, Rao J, Guo QN, Zhou Y, Meng XL, Zhu Y, Hu CL, Jiang YR, Zhang Y, Gao HY, He WJ, Xia ZJ, Wu CL, Zhang MY, Wang HY, Xie D, Cai QQ (2019) Prognostic and predictive value of a microRNA signature in adults with T-cell lymphoblastic lymphoma. Leukemia 33:2454\u20132465","journal-title":"Leukemia"},{"key":"4195_CR16","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.2015.65.4194","volume":"34","author":"G Hapgood","year":"2016","unstructured":"Hapgood G, Zheng Y, Sehn LH, Villa D, Klasa R, Gerrie AS, Shenkier T, Scott DW, Gascoyne RD, Slack GW, Parsons C, Morris J, Pickles T, Connors JM, Savage KJ (2016) Evaluation of the risk of relapse in classical Hodgkin lymphoma at event-free survival time points and survival comparison with the general population in British Columbia. J Clin Oncol 34:2493\u20132500","journal-title":"J Clin Oncol"},{"key":"4195_CR17","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/ajh.24492","volume":"91","author":"MJ Maurer","year":"2016","unstructured":"Maurer MJ, Bachy E, Ghesquieres H et al (2016) Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol 91:1096\u20131101","journal-title":"Am J Hematol"},{"key":"4195_CR18","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1200\/JCO.2017.73.8195","volume":"35","author":"MJ Maurer","year":"2017","unstructured":"Maurer MJ, Ellin F, Srour L, Jerkeman M, Bennani NN, Connors JM, Slack GW, Smedby KE, Ansell SM, Link BK, Cerhan JR, Relander T, Savage KJ, Feldman AL (2017) International assessment of event-free survival at 24 months and subsequent survival in peripheral T-cell lymphoma. J Clin Oncol 35:4019\u20134026","journal-title":"J Clin Oncol"},{"key":"4195_CR19","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","volume":"32","author":"MJ Maurer","year":"2014","unstructured":"Maurer MJ, Ghesquieres H, Jais JP et al (2014) Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol 32:1066\u20131073","journal-title":"J Clin Oncol"},{"key":"4195_CR20","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/hon.2687","volume":"37","author":"K Wudhikarn","year":"2019","unstructured":"Wudhikarn K, Bunworasate U, Julamanee J, Lekhakula A, Ekwattanakit S, Khuhapinant A, Niparuck P, Chuncharunee S, Numbenjapon T, Prayongratana K, Kanitsap N, Wongkhantee S, Makruasri N, Wong P, Norasetthada L, Nawarawong W, Sirijerachai C, Chansung K, Suwanban T, Praditsuktavorn P, Intragumtornchai T, on behalf of Thai Lymphoma Study Group (2019) Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T cell lymphoma. Hematol Oncol 37:578\u2013585","journal-title":"Hematol Oncol"},{"key":"4195_CR21","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, le Beau MM, Hellstr\u00f6m-Lindberg E, Tefferi A, Bloomfield CD (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937\u2013951","journal-title":"Blood"},{"key":"4195_CR22","first-page":"1860","volume":"31","author":"PP Carbone","year":"1971","unstructured":"Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971) Report of the Committee on Hodgkin\u2019s Disease Staging Classification. Cancer Res 31:1860\u20131861","journal-title":"Cancer Res"},{"key":"4195_CR23","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649\u2013655","journal-title":"Am J Clin Oncol"},{"key":"4195_CR24","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on Lymphoma (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579\u2013586","journal-title":"J Clin Oncol"},{"key":"4195_CR25","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1002\/cncr.30795","volume":"123","author":"M Provencio","year":"2017","unstructured":"Provencio M, Royuela A, Torrente M, Poll\u00e1n M, G\u00f3mez-Codina J, Sab\u00edn P, Llanos M, Gum\u00e1 J, Quero C, Blasco A, Aguiar D, Garc\u00eda-Arroyo FR, Lavernia J, Mart\u00ednez N, Morales M, Saenz-Cusi \u00c1, Rodr\u00edguez D, Calvo V, de la Cruz-Merino L, de la Cruz M\u00c1, Rueda A, for the Spanish Lymphoma Oncology Group (2017) Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: a study report from the Spanish Lymphoma Oncology Group. Cancer 123:3709\u20133716","journal-title":"Cancer"},{"key":"4195_CR26","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ajh.24223","volume":"91","author":"MJ Maurer","year":"2016","unstructured":"Maurer MJ, Jais JP, Ghesquieres H et al (2016) Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. Am J Hematol 91:179\u2013184","journal-title":"Am J Hematol"},{"key":"4195_CR27","doi-asserted-by":"publisher","first-page":"e346","DOI":"10.1038\/bcj.2015.69","volume":"5","author":"AJ Novak","year":"2015","unstructured":"Novak AJ, Asmann YW, Maurer MJ et al (2015) Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma. Blood Cancer J 5:e346","journal-title":"Blood Cancer J"},{"key":"4195_CR28","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.critrevonc.2010.12.003","volume":"79","author":"S Cortelazzo","year":"2011","unstructured":"Cortelazzo S, Ponzoni M, Ferreri AJ, Hoelzer D (2011) Lymphoblastic lymphoma. Crit Rev Oncol Hematol 79:330\u2013343","journal-title":"Crit Rev Oncol Hematol"},{"key":"4195_CR29","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s12032-015-0551-9","volume":"32","author":"Y Xie","year":"2015","unstructured":"Xie Y, Zhang Y, Zheng W, Wang X, Lin N, Tu M, Ping L, Ying Z, Zhang C, Liu W, Deng L, Song Y, Zhu J (2015) Outcomes of dose-adjusted Berlin-Frankfurt-Munster-90 regimen without radiotherapy in adolescents and adults with T cell lymphoblastic lymphoma. Med Oncol 32:110","journal-title":"Med Oncol"},{"key":"4195_CR30","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/pbc.24848","volume":"61","author":"YJ Gao","year":"2014","unstructured":"Gao YJ, Pan C, Tang JY, Lu FJ, Chen J, Xue HL, Zhai XW, Li J, Ye QD, Zhou M, Wang HS, Miao H, Qian XW, Xu Z, Meng JH (2014) Clinical outcome of childhood lymphoblastic lymphoma in Shanghai China 2001-2010. Pediatr Blood Cancer 61:659\u2013663","journal-title":"Pediatr Blood Cancer"},{"key":"4195_CR31","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/sj.leu.2404156","volume":"20","author":"E Jabbour","year":"2006","unstructured":"Jabbour E, Koscielny S, Sebban C, Peslin N, Patte C, Gargi T, Biron P, Ferm\u00e9 C, Bourhis JH, Vantelon JM, Arnaud P, Ribrag V (2006) High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL). Leukemia 20:814\u2013819","journal-title":"Leukemia"},{"key":"4195_CR32","doi-asserted-by":"publisher","first-page":"573","DOI":"10.4143\/crt.2019.542","volume":"52","author":"C Li","year":"2020","unstructured":"Li C, Wuxiao ZJ, Chen X, Chen G, Lu Y, Xia Z, Liang Y, Wang H (2020) A modified NHL-BFM-95 regimen produces better outcome than HyperCVAD in adult patients with T-lymphoblastic lymphoma, a two-institution experience. Cancer Res Treat 52:573\u2013585","journal-title":"Cancer Res Treat"},{"key":"4195_CR33","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.3324\/haematol.2015.139162","volume":"102","author":"E Landmann","year":"2017","unstructured":"Landmann E, Burkhardt B, Zimmermann M, Meyer U, Woessmann W, Klapper W, Wrobel G, Rosolen A, Pillon M, Escherich G, Attarbaschi A, Beishuizen A, Mellgren K, Wynn R, Ratei R, Plesa A, Schrappe M, Reiter A, Bergeron C, Patte C, Bertrand Y (2017) Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma. Haematologica 102:2086\u20132096","journal-title":"Haematologica"},{"key":"4195_CR34","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/bjh.12460","volume":"162","author":"AM Termuhlen","year":"2013","unstructured":"Termuhlen AM, Smith LM, Perkins SL, Lones M, Finlay JL, Weinstein H, Gross TG, Abromowitch M (2013) Disseminated lymphoblastic lymphoma in children and adolescents: results of the COG A5971 trial: a report from the Children\u2019s Oncology Group. Br J Haematol 162:792\u2013801","journal-title":"Br J Haematol"},{"key":"4195_CR35","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.ejca.2008.02.011","volume":"44","author":"A Uyttebroeck","year":"2008","unstructured":"Uyttebroeck A, Suciu S, Laureys G, Robert A, Pacquement H, Ferster A, Marguerite G, Mazingue F, Renard M, Lutz P, Rialland X, Mechinaud F, Cav\u00e9 H, Baila L, Bertrand Y, Children's Leukaemia Group (CLG) of the European Organisation for Research and Treatment of Cancer (EORTC) (2008) Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial. Eur J Cancer 44:840\u2013846","journal-title":"Eur J Cancer"},{"key":"4195_CR36","doi-asserted-by":"publisher","first-page":"680","DOI":"10.3109\/0284186X.2013.855816","volume":"53","author":"H Bersvendsen","year":"2014","unstructured":"Bersvendsen H, Kolstad A, Blystad AK, Aurlien E, Foss\u00e5 A, Kval\u00f8y SO, Holte H, Lauritzsen GF (2014) Multimodal treatment with ALL-like chemotherapy, auto-SCT and radiotherapy for lymphoblastic lymphoma. Acta Oncol 53:680\u2013687","journal-title":"Acta Oncol"},{"key":"4195_CR37","doi-asserted-by":"publisher","first-page":"927","DOI":"10.3109\/0284186X.2014.889850","volume":"53","author":"F Ellin","year":"2014","unstructured":"Ellin F, Jerkeman M, Hagberg H, Relander T (2014) Treatment outcome in T-cell lymphoblastic lymphoma in adults - a population-based study from the Swedish lymphoma registry. Acta Oncol 53:927\u2013934","journal-title":"Acta Oncol"},{"key":"4195_CR38","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1002\/cncr.28930","volume":"120","author":"ME Rytting","year":"2014","unstructured":"Rytting ME, Thomas DA, O'Brien SM, Ravandi-Kashani F, Jabbour EJ, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Cortes JE, Borthakur G, Garris R, Cardenas-Turanzas M, Schroeder K, Jorgensen JL, Kornblau SM, Kantarjian HM (2014) Augmented Berlin-Frankfurt-Munster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer 120:3660\u20133668","journal-title":"Cancer"},{"key":"4195_CR39","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1200\/JCO.2001.19.11.2927","volume":"19","author":"JW Sweetenham","year":"2001","unstructured":"Sweetenham JW, Santini G, Qian W, Guelfi M, Schmitz N, Simnett S, Nagler A, Holte H, Kvaloy S, Bruzzi P, Goldstone AH (2001) High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation\/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. J Clin Oncol 19:2927\u20132936","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04195-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04195-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04195-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T23:14:59Z","timestamp":1627168499000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04195-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,25]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4195"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04195-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2020,7,25]]},"assertion":[{"value":"19 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of Cancer Hospital, Chinese Academy of Medical Sciences\u00a0& Peking Union Medical College.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}]}}